Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma

Leukemia

Volumn 14, Issue 8, 2000, Pages 1477-1482

  Bertolini, F ^a   Fusetti, L ^a   Rabascio, C ^a   Cinieri, S ^a   Martinelli, G ^a   Pruneri, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cyclophosphamide; Green tea; NOD SCID mice; Non Hodgkin's lymphoma

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FOOD INTAKE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TEA; TUMOR CELL; TUMOR GROWTH;

EID: 0033859756     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401854     Document Type: Article

References (33)

1. Tea and cancer (review)
2. Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea
3. Modulation of cancer chemotherapy by green tea
4. Why drinking tea could prevent cancer
5. Tumor invasion: Molecular shears blunted by green tea
6. Epigallocatechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signalling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cel
7. Angiogenesis inhibited by drinking tea
8. Angiogenesis in cancer, vascular, rheumatoid and other diseases
9. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
10. Angiogenesis in myelodysplastic syndromes
11. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
12. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects
13. False human hematopoietic cell lines: Cross-contaminations and misinterpretations
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
15. Inhibitory effect of green tea in the drinking water on tumorigenesis by ultraviolet light and 12-0-tetradecanoylphorbol-13-acetate in the skin of SKH-1 mice
16. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques
17. Human myeloid and lymphoid malignancies in the NOD/SCID mouse model: Frequency of apoptotic cells in solid tumors, efficiency and speed of engraftment correlate with vascular endothelial growth factor production
18. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
19. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
20. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
21. A high pretreatment serum basic-fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
22. Organ-site dependent expression of b-FGF in human renal cell carcinoma cells
23. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
24. Incipient angiogenesis (editorial)
25. Endostatin: An endogenous inhibitor of angiogenesis and tumour growth
26. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induce tumor and endothelial cell apoptosis
27. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts
28. Antitumor activity of thalidomide in refractory multiple myeloma
29. Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis
30. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes
31. Antiangiogenesis for cancer therapy
32. Phase I and clinical pharmacology study of green tea extract (GTE) in patients with advanced solid tumors. Proceedings of the Meeting of the American Society of Clinical Oncology
33. Phase I trial of green tea extract (GTE) in adult patients with solid tumors. Proceedings of the Meeting of the American Society of Clinical Oncology